HeartFlow, Inc. is recommended as a buy due to its AI-enabled platform that enhances coronary artery disease diagnosis through tools like FFRCT and Plaque Analysis. The latter is validated and soon to have its own billing code, expanding the market and revenue from existing scans. With only about 2% market penetration and 41% year-over-year revenue growth, HeartFlow shows significant long-term growth potential despite risks. The current valuation of roughly 8.4 times forward revenue is considered justified by the company's expanding product suite and clinical integration.
Bitcoin surged to $65,340 on August 7 after US July nonfarm payrolls unexpectedly fell by 23,000, the first monthly job loss since February. This weaker employment data reduced the probability of a Federal Reserve rate hike in September from 55% to 4...
In July, the US unemployment rate decreased slightly to 4.1%, the lowest since January 2025, despite weaker-than-expected non-farm payrolls showing a loss of 23,000 jobs. Meanwhile, US manufacturing activity expanded at its fastest pace in over four ...
A $100 million hack on Coldcard bitcoin hardware wallets has revealed nearly 5,000 security vulnerabilities across 400 crypto projects, including 85 critical bugs. This has shaken investor confidence and kept bitcoin prices near recent lows. A volunt...
Arm Holdings is positioned to benefit significantly from the growing AI and AGI CPU market, with demand doubling quarter-over-quarter and over $2 billion in secured orders from major partners like Meta and Oracle. Management aims for $25 billion in r...
Fuel Labs has launched its mainnet featuring a parallel execution engine for Ethereum-compatible applications. This innovation allows multiple transactions to be processed simultaneously rather than sequentially, enhancing throughput for complex dece...
